- Home
- EXEL vs HBANL Comparison
EXEL vs HBANL Comparison
Compare EXEL & HBANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EXEL | HBANL |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | United States |
| Employees | N/A | 20242 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | N/A |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | EXEL | HBANL |
|---|---|---|
| Price | $43.47 | $25.35 |
| Analyst Decision | Buy | |
| Analyst Count | 23 | 0 |
| Target Price | ★ $45.18 | N/A |
| AVG Volume (30 Days) | ★ 2.5M | N/A |
| Earning Date | 02-10-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.55 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $2,288,218,000.00 | N/A |
| Revenue This Year | $9.79 | N/A |
| Revenue Next Year | $12.01 | N/A |
| P/E Ratio | $18.34 | ★ N/A |
| Revenue Growth | ★ 9.93 | N/A |
| 52 Week Low | $31.90 | N/A |
| 52 Week High | $49.62 | N/A |
Technical Indicators
Market Signals| Indicator | EXEL | HBANL |
|---|---|---|
| Relative Strength Index (RSI) | 50.48 | 40.67 |
| Support Level | $40.83 | $25.12 |
| Resistance Level | $47.24 | $25.65 |
| Average True Range (ATR) | 1.10 | 0.22 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 43.69 | 30.23 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About HBANL Huntington Bancshares Incorporated Depositary Shares Each Representing a 1/40th Interest in a Share of 6.875% Series J Non-Cumulative Perpetual Preferred Stock
Huntington is a regional US bank with around $208 billion in assets and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.